Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 6/20 | 0.37 |
| ▸ | KDM1A | O60341 | 3/20 | 0.37 |
| ▸ | MAOB | P27338 | 3/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29330733 | 0.90 | LMNA (0.36) | LMNASMYD3KDM1AMAOBMAOA | |
| SCHEMBL24274074 | 0.90 | LMNA (0.39) | LMNASMYD3KDM1AMAOBMAOA | |
| SCHEMBL24139699 | 0.90 | LMNA (0.39) | LMNASMYD3KDM1AMAOBMAOA | |
| SCHEMBL29338614 | 0.89 | SMYD3 (0.39) | LMNASMYD3KDM1AMAOBMAOA | |
| SCHEMBL29330475 | 0.88 | SMYD3 (0.38) | LMNASMYD3KDM1AMAOBMAOA | |
| SCHEMBL24273836 | 0.87 | LMNA (0.41) | LMNASMYD3KDM1AMAOBMAOA | |
| SCHEMBL24139690 | 0.87 | LMNA (0.41) | LMNASMYD3KDM1AMAOBMAOA | |
| SCHEMBL24139791 | 0.87 | LMNA (0.41) | LMNASMYD3KDM1AMAOBMAOA | |
| SCHEMBL29330729 | 0.87 | SMYD3 (0.39) | LMNASMYD3KDM1AMAOBMAOA | |
| SCHEMBL29330730 | 0.87 | SMYD3 (0.39) | LMNASMYD3KDM1AMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | IFNAR1, NR4A3, NR0B2 | LMNA 3555/4885SMYD3 1144/4885KDM1A 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.